Indeed, a similar synergistic effect against cancer cell proliferation is obtained combining gemcitabine and PD98059, a MEK1/2 inhibitor that can block activation of downstream ERK-1/2 (Boucher et al, 2000), confirming the importance of this signal pathway in the observed experimental data. Here, MAPK3 is linked to cancer.